<DOC>
	<DOCNO>NCT01176058</DOCNO>
	<brief_summary>In treatment patient candidemia and/or form invasive candidiasis , Anidulafungin least effective safe Fluconazole .</brief_summary>
	<brief_title>A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis</brief_title>
	<detailed_description>To support anidulafungin NDA China Due challenge subject recruitment result protract study course , Pfizer Inc. decide terminate trial A8851023 prematurely base recommendation senior management team November 8 , 2011 . The decision terminate trial base safety concern . All investigator verbally inform study team since November 8 , 2011 stop subject recruitment soon possible . All 17 enrol subject follow safety issue safety concern present data subject .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Presence candidemia invasive candidiasis . Presence one sign symptoms acute fungal infection . Subjects receive great 48 hour systemic antifungal treatment Candida infection enrol . Subjects hypersensitivity echinocandins azole therapy drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Phase 3b</keyword>
	<keyword>Efficacy Safety evaluation Anidulafungin</keyword>
	<keyword>ICC</keyword>
</DOC>